0001649094-24-000054.txt : 20240820 0001649094-24-000054.hdr.sgml : 20240820 20240820164955 ACCESSION NUMBER: 0001649094-24-000054 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240819 FILED AS OF DATE: 20240820 DATE AS OF CHANGE: 20240820 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GUGGENHIME ANDREW CENTRAL INDEX KEY: 0001230724 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39323 FILM NUMBER: 241225905 MAIL ADDRESS: STREET 1: C/O VAXCYTE, INC. STREET 2: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vaxcyte, Inc. CENTRAL INDEX KEY: 0001649094 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 464233385 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 650-837-0111 MAIL ADDRESS: STREET 1: 825 INDUSTRIAL ROAD, STE. 300 CITY: SAN CARLOS STATE: CA ZIP: 94070 FORMER COMPANY: FORMER CONFORMED NAME: SutroVax, Inc. DATE OF NAME CHANGE: 20150724 4 1 wk-form4_1724186989.xml FORM 4 X0508 4 2024-08-19 0 0001649094 Vaxcyte, Inc. PCVX 0001230724 GUGGENHIME ANDREW C/O VAXCYTE, INC. 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070 0 1 0 0 PRESIDENT AND CFO 1 Common Stock 2024-08-19 4 M 0 8000 5.35 A 104720 D Common Stock 2024-08-19 4 S 0 4994 78.248 D 99726 D Common Stock 2024-08-19 4 S 0 3006 79.135 D 96720 D Stock Option (right to buy) 5.35 2024-08-19 4 M 0 8000 0 D 2030-05-11 Common Stock 8000 328827 D The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted June 30, 2023. The price reported is a weighted-average price. The shares were sold at prices ranging from $77.875 to $78.78. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. The shares were sold at prices ranging from $78.88 to $79.66. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. 1/4 of the shares subject to the option vested on May 1, 2021, and 1/48 of the shares vest monthly thereafter. Andrew Guggenhime, by /s/ Peter N. Efremenko, Attorney-In-Fact 2024-08-20